FdaApplication
BLA 125433
Identifiers
- fda_app_no: BLA125433
Properties
| Property | Value |
|---|---|
| applicant_name | Janssen Biotech, Inc. |
| application_type | BLA |
| approval_date | 2013-07-18 |
Revenue by product
SIMPONI ARIA
| Period | Revenue |
|---|---|
| Q2 2026 | $618.0M |
| Q1 2026 | $647.0M |
| Q4 2025 | $632.0M |
| Q3 2025 | $687.0M |
| Q2 2025 | $690.0M |
| Q1 2025 | $659.0M |
| Q4 2024 | $583.0M |
| Q3 2024 | $516.0M |
| Q2 2024 | $537.0M |
| Q1 2024 | $554.0M |
| Q4 2023 | $502.0M |
| Q3 2023 | $629.0M |
| Q2 2023 | $529.0M |
| Q1 2023 | $537.0M |
| Q4 2022 | $502.0M |
| Q3 2022 | $545.0M |
| Q2 2022 | $566.0M |
| Q1 2022 | $571.0M |
| Q4 2021 | $559.0M |
| Q3 2021 | $571.0M |
| Q2 2021 | $584.0M |
| Q1 2021 | $562.0M |
| Q4 2020 | $576.0M |
| Q3 2020 | $592.0M |
| Q2 2020 | $546.0M |
| Q1 2020 | $529.0M |
| Q4 2019 | $515.0M |
| Q3 2019 | $586.0M |
| Q2 2019 | $563.0M |
| Q1 2019 | $524.0M |
| Q4 2018 | $482.0M |
| Q3 2018 | $536.0M |
| Q2 2018 | $548.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| SIMPONI ARIA | GOLIMUMAB | 50MG/4ML (12.5MG/ML) | INJECTABLE;INJECTION |
1 product